The FDA’s newest recommendations on clinical and CMC considerations for Investigational New Drug (IND) applications for the development of individualized ASO drug products for severely debilitating or life-threatening diseases join ASO guidance from earlier last year to further clarify the regulatory pathway for diseases identified in very few patients.
2021 brought more challenges and opportunities than ever before. From the starts and stops of opening workplaces, schools and economies to managing an overflowing email inbox, it can be challenging to keep up with all the information you need.
One in 10 Americans is affected by rare diseases—more than half of which are children—and approximately 95% of the more than 7,000 rare diseases have no available treatments. To advance the development of rare disease treatments, the Food and Drug Administration (FDA) Office of Orphan Products Development, OOPD.
MMS has just concluded its second annual Global Champions of Change Competition (G3C), where colleagues from all MMS regions submitted innovative ideas based on our tradition of providing high-quality, efficient services to our clients to help discover and market life-changing medicines to patients around the world.
The clinical development industry is an ever-changing field. It’s crucial to stay ahead of industry changes and ensure compliance with the needs of health authorities. Experienced medical writers understand the purpose of a trial and work closely with the study team to recognize efficiencies that may impact the study design or the long-term success of the clinical study.
Why is drug development and research in the context of rare disease frequently more difficult to address? In this blog, we will outline some of the challenges with rare disease programs.
For Sponsors planning to manufacture or distribute a medical device in the US, understanding regulatory requirements is of the utmost importance. Medical device development and approval are regulated by the FDA, under the jurisdiction of the Center for Devices and Radiologic Health (CDRH).
On 31 July 2021, the European Commission published a notice in the Official Journal of the European Union announcing that the EU Portal and Database, a key component of the Clinical Trial Information System (CTIS), is fully functional.
For its leadership and culture as a clinical research organization (CRO) in the pharmaceutical industry, MMS has received much recognition and praise recently.
To uncover some of the reasons behind this success, we recently sat down with Prasad M. Koppolu, Chief Operating Officer (COO) at MMS
How to Maximize FSP Partnerships - Scalability, Innovation, and Efficiencies. by Donnelle LaDouceur, Director of Functional Service Solutions FSP partnership models, when developed to find the right level of oversight, scale, pricing, and governance to meet...
CONNECT WITH US